Thermo Fisher Scientific Stock

Equities

TMO

US8835561023

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 11:52:10 2024-05-23 am EDT 5-day change 1st Jan Change
589.5 USD -0.22% Intraday chart for Thermo Fisher Scientific -1.41% +10.91%
Sales 2024 * 43.01B Sales 2025 * 46.08B Capitalization 226B
Net income 2024 * 6.15B Net income 2025 * 6.97B EV / Sales 2024 * 5.8 x
Net Debt 2024 * 23.99B Net Debt 2025 * 19.18B EV / Sales 2025 * 5.31 x
P/E ratio 2024 *
37.2 x
P/E ratio 2025 *
31.9 x
Employees 122,000
Yield 2024 *
0.25%
Yield 2025 *
0.28%
Free-Float 86.04%
More Fundamentals * Assessed data
Dynamic Chart
Thermo Fisher Scientific Keeps Quarterly Dividend of $0.39 a Share, Payable July 15 to Shareholders of Record on June 14 MT
Thermo Fisher Scientific Introduces Array-Based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions CI
Transcript : Thermo Fisher Scientific Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM
UK Competition Regulator Opens Probe on Thermo Fisher, Olink Merger MT
UK Competition Watchdog Opens Probe on Thermo Fisher Scientific's Acquisition of Olink MT
UK's CMA kicks off probe into Thermo Fisher-Olink deal RE
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip RE
Thermo Fisher Scientific Insider Sold Shares Worth $5,737,356, According to a Recent SEC Filing MT
Jefferies Adjusts Price Target on Thermo Fisher Scientific to $600 From $540 MT
Thermo Fisher Scientific Insider Sold Shares Worth $1,135,880, According to a Recent SEC Filing MT
HSBC Raises Thermo Fisher Scientific's Price Target to $670 From $660 MT
Bio-Techne to Enter Product Distribution Deal With Thermo Fisher Scientific MT
Bio-Techne Corporation Announces New Distribution Agreement with Thermo Fisher Scientific CI
Raymond James Adjusts Price Target on Thermo Fisher Scientific to $650 From $605, Keeps Outperform Rating MT
Redburn Atlantic Adjusts Price Target on Thermo Fisher Scientific to $620 From $615 MT
More news
1 day-0.27%
1 week-1.17%
Current month+3.77%
1 month+2.71%
3 months+4.50%
6 months+20.25%
Current year+11.18%
More quotes
1 week
585.32
Extreme 585.32
597.24
1 month
565.23
Extreme 565.23
602.00
Current year
527.32
Extreme 527.32
603.82
1 year
415.60
Extreme 415.6
603.82
3 years
415.60
Extreme 415.6
672.34
5 years
250.21
Extreme 250.21
672.34
10 years
107.33
Extreme 107.33
672.34
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 01-10-31
Director of Finance/CFO 57 01-05-31
Chief Tech/Sci/R&D Officer - 18-12-31
Members of the board TitleAgeSince
Chief Executive Officer 56 01-10-31
Director/Board Member 67 12-03-29
Director/Board Member 62 22-02-28
More insiders
Date Price Change Volume
24-05-23 588.7 -0.36% 281 452
24-05-22 590.8 +0.12% 872,991
24-05-21 590.1 -0.65% 1,133,164
24-05-20 594 -0.22% 805,710
24-05-17 595.3 -0.31% 1,398,449

Delayed Quote Nyse, May 23, 2024 at 10:18 am EDT

More quotes
Thermo Fisher Scientific Inc. specializes in the design, manufacturing and marketing of laboratory and scientific equipments. Net sales (including intragroup) break down by family of products as follows: - laboratory equipments (70%). Moreover, the group proposes chemical products (reagents, solvent, salts, etc.), consumable products (tubes, funnels, vials, etc.), as well as conditioning, warehousing, storage, etc.; - diagnostics equipment and products (15.3%); - scientific analysis equipments (14.7%): analyzer (of water, gas, grounds, etc.), mass spectrometers, molecular spectroscopes, microscopes, manometers, samplers, microbiology equipments, reactive agents, etc. Net sales break down by source of income into products sales (78.5%) and services (21.5%). Net sales break down geographically as follows: North America (53%), Europe (25.7%), Asia-Pacific (18.1%) and others (3.2%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
590.8 USD
Average target price
627.3 USD
Spread / Average Target
+6.17%
Consensus